All In Biotech

Drug Trial Radar · NCT07065773

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

An Open Label Study to Investigate the Safety and Tolerability of Trichostatin A in Patients With Mild to Severe Onychomycosis

Last checked: Nov 20, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

May 5, 2025

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution. The efficacy objectives of the study will be assessed using fungal culture testing, Neutral Red Staining (NRS) microscopy examination, and KOH microscopy examination after 4 weeks of treatment with VTR-297.

Conditions

  • Onychomycosis of Toenail

Interventions

  • Trichostatin ADrug

    Topical Study Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 24 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Vanda Investigational Site

    Fremont, California

  • Vanda Investigational Site

    Denver, Colorado

  • Vanda Investigational Site

    New Brighton, Minnesota

  • Vanda Investigational Site

    Pflugerville, Texas

  • Vanda Investigational Site

    Forest, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.